Finally, intertumoral heterogenicity in GBM patients is another fundamental issue that has to be considered [154], pointing to the requirement for studies aimed at improving patient stratification and identifying which GBM patients could indeed benefit from SRC targeting. This evidence concerns the gene SRC and glioblastoma.